NCT02705196View on ClinicalTrials.gov

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Pancreatic Cancer

Interventions

GENETIC

delolimogene mupadenorepvec

oncolytic virus encoding TMZ-CD40L and 4-1BBL

DRUG

gemcitabine

chemotherapy

DRUG

nab-paclitaxel

chemotherapy

BIOLOGICAL

atezolizumab

anti-PD-L1 antibody

Trial Locations (2)

77030

Baylor College of Medicine, Houston

Baylor St Luke's Medical Center, Houston

Sponsors

Lead Sponsor

Lokon Pharma AB

All Listed Sponsors

lead

Lokon Pharma AB

INDUSTRY

NCT02705196 - LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | Biotech Hunter | Biotech Hunter